Earnings summaries and quarterly performance for Actinium Pharmaceuticals.
Executive leadership at Actinium Pharmaceuticals.
Board of directors at Actinium Pharmaceuticals.
Research analysts covering Actinium Pharmaceuticals.
Recent press releases and 8-K filings for ATNM.
Actinium Pharmaceuticals Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer
ATNM
New Projects/Investments
Revenue Acceleration/Inflection
- Actinium Pharmaceuticals (ATNM) announced superior preclinical efficacy of its lead solid tumor program, ATNM-400, in non-small cell lung cancer (NSCLC).
- ATNM-400 demonstrated 3-5 times greater tumor growth inhibition as a monotherapy compared to current standard-of-care EGFR-mutant NSCLC therapies, including osimertinib, Dato-DXd, and amivantamab.
- In combination with osimertinib, ATNM-400 achieved complete tumor regression in 100% of tumor-bearing animals, indicating synergistic activity.
- The company highlights the multi-tumor potential of ATNM-400, which is also being developed for prostate cancer, and aims to address the significant unmet need in NSCLC where existing therapies generated approximately $7 billion in sales in 2024 but face resistance issues.
Oct 27, 2025, 11:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more